Antimicrobial resistance pattern of Pseudomonas aeruginosa in clinical isolates from ICU patients
© Antypa et al; licensee BioMed Central Ltd. 2009
Published: 13 March 2009
Pseudomonas aeruginosa remains one of the most important pathogens in the nosocomial setting, where it is a common causative agent of bacteremia [1, 2]. The aim of this study was to evaluate the antimicrobial resistance of Pseudomonas spp. strains isolated from inpatients hospitalized in the ICU of our hospital throughout a 3-year period.
A total of 175 clinical isolates of Pseudomonas spp. collected from January 2006 to December 2008 were investigated in this study. Each isolate was obtained from a different patient. Identification and routine antibiograms of the isolates were carried out using the Vitek 2 automated System (BioMerieux®, Marcy I'Etolie, France). The minimum inhibitory concentrations of imipenem, meropenem and colistin were also determined by the agar dilution method according to Clinical Laboratory Standards Institute guidelines.
The isolates included in our study originated from blood cultures 70 (40%), urine 53 (30.3%), bronchial aspirates 23 (13.1%), central venous catheters 18 (10.3%) and others 11 (6.3%). The resistance rates changed from 2006 to 2008 as follows: amikacin: 72 to 83%, aztreonam: 90 to 95%, ceftazidime: 81 to 89%, ciprofloxacin: 79 to 85%, colistin: 0 to 0%, meropenem: 72 to 83%, imipenem: 72 to 83%, netilmicin: 72 to 83%, piperacillin/tazobactam: 71 to 80%, tobramycin: 72 to 83%, ticarcillinlin/clavulanic acid: 71 to 80%.
Pseudomonas spp. infections are particularly serious for incubated ICU patients with 40 to 50% mortality rates. In our hospital, the percentage of Pseudomonas spp. multiresistant isolates has increased dramatically over the past 3 years. The majority of isolates were resistant to 15 or more antibiotics. What is most worrying is the fact that there is a prevalence of a multiresistant phenotype that was only sensitive to colistin. The emergance and rapid spread of multidrug-resistant isolates of Pseudomonas spp. are of great concern worldwide. It is necessary to limit the overuse of antibiotics and to implement a new antibiotic policy.
- Tan TY, Ng LSY, Kwang LL: Evaluation of disc susceptibility tests performed directly from positive blood cultures. J Clin Pathol 2008, 61: 343-346. 10.1136/jcp.2007.050757View ArticleGoogle Scholar
- Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H: Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa . Diagn Microbiol Infect Dis 1997, 29: 81-86. 10.1016/S0732-8893(97)00123-5View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd.